Docket No.: PF-0527-1 DIV

consisting of:

a) a naturally-occurring amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:1, and

b) a naturally-occurring amino acid sequence having at least 90% amino acid sequence identity to SEQ ID NO:2.

- 14. A purified antibody which specifically binds to a polypeptide of claim 1.
- 15. A purified agonist which specifically binds to and modulates the activity of a polypeptide of claim 1.
- 16. A purified antagonist which specifically binds to and modulates the activity of a polypeptide of claim 1.
- 17. A method for treating or preventing a neoplastic disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.
- 18. A method for treating or preventing a reproductive disorder, the method comprising administering to a subject in need of such treatment an effective amount of the antagonist of claim 16.
- 21. A polypeptide of claim 1, having the amino acid sequence of SEQ ID NO:1 or SEQ ID NO:2.
- 22. A composition comprising a polypeptide of claim 21 in conjunction with a suitable pharmaceutical carrier.
 - 23. An isolated polynucleotide selected from the group consisting of:
 - a) a polynucleotide sequence of SEQ ID NO:3,


Docket No.: PF-0527-1 DIV

- b) a polynucleotide sequence of SEQ ID NO:4,
- c) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:3,
- d) a naturally-occurring polynucleotide sequence having at least 90% sequence identity to the sequence of SEQ ID NO:4, and
 - e) a polynucleotide sequence complementary to a), b), c) or d).
- 24. A method of detecting a target polynucleotide in a sample, said target polynucleotide having the sequence of a polynucleotide of claim 23, comprising

hybridizing the sample with a probe comprising at least 16 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide, and

detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

- 25. A method of claim 24, wherein the probe comprises at least 30 contiguous nucleotides.
- 26. A method of claim 24, wherein the probe comprises at least 60 contiguous nucleotides.
- 27. A composition comprising a polypeptide of claim 1 in conjunction with a suitable pharmaceutical carrier.



29. A composition comprising the polypeptide of claim 28 in conjunction with a suitable

Docket No.: PF-0527-1 DIV

pharmaceutical carrier.

30. A method of screening for a compound that specifically binds to the polypeptide of claim 21, said method comprising the steps of:

- a) combining the polypeptide of claim 21 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 21 to the test compound, thereby identifying a compound that specifically binds to the polypeptide of claim 21.
- 31. A method for producing an antibody that specifically binds to the polypeptide of claim 21, the method comprising:
- a) inoculating a mammal with the polypeptide of claim 21 under conditions such that the mammal makes antibodies that bind specifically to the polypeptide of claim 21, and
 - b) isolating said antibodies from said mammal.
- 32. A method for determining whether a sample contains a polypeptide having the amino acid sequence of either SEQ ID NO:1 or SEQ ID NO:2, the method comprising:
 - a) contacting the antibody produced by the method of claim 31 with said sample, and
- b) detecting specific binding of said antibody to said sample, wherein the presence of specific binding indicates the presence of a polypeptide having the amino acid sequence of either SEQ ID NO:1 or SEQ ID NO:2 in said sample.

77454 4 09/397,558